Speciociliatine: Receptors, Human Exposure, Metabolism & Safety Gaps

What is speciociliatine?

Speciociliatine is an indole alkaloid found in kratom and a stereoisomer of mitragynine: the compounds differ in spatial configuration despite their close chemical relationship. It is not 7-OH, pseudoindoxyl, or a standardized description of a kratom product. Chemical proximity alone cannot transfer a clinical conclusion between them. Receptor study

Safety boundary: No safe consumer dose of isolated speciociliatine is established here. This is an evidence review, not a treatment or buying recommendation. Read the medical disclaimer.

Human evidence

A small healthy-adult pharmacokinetic study measured speciociliatine after mixed kratom tea. That provides human exposure evidence; it does not isolate speciociliatine's effects or establish a therapeutic benefit. The tea contained multiple alkaloids, so any observed product-level response cannot be assigned to this one constituent. Human PK study

No controlled efficacy trial of isolated speciociliatine was identified in the sources reviewed for this page. A brief, small exposure study also cannot resolve uncommon adverse events, chronic use, or safety in patients taking medications. Human-derived cells and microsomes are laboratory evidence, even when a paper names a human receptor.

Preclinical evidence

Receptor experiments support investigating speciociliatine as a pharmacologically distinct alkaloid. They address molecular activity under particular assay conditions, rather than relief of a human symptom. Animal and laboratory findings should therefore remain separate from clinical efficacy and from the subjective effects of a multi-alkaloid product.

Pharmacology and receptors

The findings are assay-dependent. A 2016 study found no measurable opioid agonism for speciociliatine in its human-receptor assays, while a 2026 study reported MOR partial agonism and KOR agonism in cAMP assays. These are conflicting functional observations, not a settled human potency ranking. 2016 experiments · 2026 experiments

Binding affinity measures receptor interaction; agonism measures activation. Neither by itself establishes analgesia, intoxication, respiratory safety, or the contribution to a particular kratom preparation. Comparisons must also account for receptor expression, cellular background, and the signaling endpoint. Calling a receptor human describes the experimental target, not a clinical trial population.

Metabolism and pharmacokinetics

A 2022 metabolism study used microsomes and hepatocytes from humans and preclinical species. It identified oxidation and O-demethylation and implicated CYP3A4 in clearance. This supports a plausible susceptibility to enzyme-modifying drugs, without measuring the size of a clinical interaction. Metabolism study

The human tea study supplies a separate exposure observation. Laboratory intrinsic clearance and oral exposure after a mixture answer different questions; neither defines isolated-compound dosing, reliable onset, or a universally applicable half-life. Product composition and the study setting must stay attached to any PK interpretation.

Safety

The available evidence does not establish long-term cardiopulmonary, liver, reproductive, or developmental safety for isolated speciociliatine. Receptor signaling patterns cannot establish a respiratory safety advantage. FDA warnings about kratom are relevant product context but cannot determine which constituent caused an individual adverse event. FDA

Dependence and withdrawal

The studies cited here do not quantify isolated-speciociliatine dependence or withdrawal in humans. Reports involving kratom mixtures cannot identify this alkaloid's individual contribution. Opioid-receptor activity makes this a research question; it is not sufficient evidence either to diagnose a compound-specific syndrome or to advertise the compound as non-addictive.

Interactions

CYP3A4 involvement is a laboratory interaction signal. It does not establish a clinically tested list of safe combinations or prove that speciociliatine produces the same interactions as mitragynine. Medication review needs the actual product, other alkaloids, and the person's clinical context. No combination regimen follows from this evidence. Metabolism study

Regulatory status — September 30, 2026

FDA has not approved kratom for medical use. This does not establish a distinct approved indication for speciociliatine. This review provides no comprehensive federal/state legal determination for isolated speciociliatine; botanical-product rules, compound scheduling, and therapeutic approval are separate questions. Retail availability does not answer them. FDA

Evidence gaps

Priorities include independent reconciliation of receptor assays, isolated-compound human PK, medication-interaction studies, and controlled safety and efficacy research. An evidence summary should retain both the older null assay and the newer activity result rather than selecting whichever supports a preferred product claim.

Related compounds

• Mitragynine: the main alkaloid and human-evidence anchor.
• Speciogynine and mitraciliatine: distinct stereochemical relatives.
• 7-Hydroxymitragynine and mitragynine pseudoindoxyl: distinct derivatives with separate harm evidence.
• 3-Dehydromitragynine: a separate metabolism/toxicology question.

Explore the substance-use evidence hub for clinical safety context. Primary references and identifiers are listed below.